Memantinhydrochlorid Puren (Memantine Hydrochloride)

Memantine Hydrochloride acts on the glutamatergic pathway to modulate neuronal excitotoxicity in neurodegenerative disease.

• Alzheimer’s disease: improves cognition, daily functioning and behavioral symptoms in patients with moderate to severe disease.

• Memantine Hydrochloride binds to the NMDA (N‑methyl‑D‑aspartate) receptor at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By blocking excessive calcium influx during pathological activation, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, thereby slowing disease‑related neurodegeneration.

Memantine Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet.
• Confusion: occasional disorientation, usually improves over time.
• Fatigue: feeling unusually tired or weak.
• Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects

• Seizures: rare but may occur, requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hepatic failure: signs of liver dysfunction such as jaundice.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Psychosis: new or worsening hallucinations or delusions.

Before prescribing Memantinhydrochlorid Puren, clinicians should consider several safety factors.

• Renal impairment: adjust dose or monitor serum levels in patients with reduced kidney function.
• Hepatic impairment: use with caution in patients with liver disease.
• History of seizures: evaluate risk and monitor closely.
• Elderly patients: start at low dose and titrate slowly.
• Concomitant NMDA antagonists: avoid combined use due to additive effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine Hydrochloride can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can lead to excessive CNS depression.
• Other NMDA antagonists: heightened risk of adverse neurological effects.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may reduce cognitive benefit of memantine.
• CNS depressants (e.g., benzodiazepines): monitor for increased sedation.
• Diuretics: may raise serum memantine concentrations; adjust dose if needed.